News

BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year
Q1 2025 Management View CEO Jon Stonehouse highlighted the company’s strong performance, with ORLADEYO generating $134 ...
BioCryst Rises on Strong Sales of Rare-Disease Drug
In the first quarter, BioCryst swung to a profit of $32,000, or less than a penny a share from a loss of $35.4 million, or 17 cents a share, a year earlier. Revenue surged 57% to $145.5 million, ...
The Manila Times10h
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported ...
BioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)- -Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million- -Company now expects to be profitable for full ...
Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on the development ...
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company ...